{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:02:23Z","timestamp":1753894943231,"version":"3.41.2"},"reference-count":31,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS\u00a0+\u00a0OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR\u00a0+\u00a0OAD) among adults with treatment-resistant depression (TRD).\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            An Excel-based model was developed to estimate the cost-per-remitter for ESK NS\u00a0+\u00a0OAD and QTP XR\u00a0+\u00a0OAD from the perspective of a US commercial insurance plan and Medicaid. Remission and response rates were estimated in 4-week intervals over 32\u00a0weeks using data from the ESCAPE-TRD phase IIIb clinical trial comparing ESK NS\u00a0+\u00a0OAD versus QTP XR\u00a0+\u00a0OAD in adults with TRD. Direct healthcare costs were sourced from health economic literature and the RED BOOK\n            <jats:sup>\u00ae<\/jats:sup>\n            drug pricing database. Indirect costs were derived from a separate analysis of ESCAPE-TRD using the Work Productivity and Activity Impairment: Depression questionnaire. Adults not remitting\/responding either stayed on current treatment or discontinued current treatment and initiated either augmented therapy with antipsychotics or repetitive transcranial magnetic stimulation. In a scenario analysis, all individuals who did not achieve response and discontinued treatment initiated repetitive transcranial magnetic stimulation.\n            <jats:bold>Results:<\/jats:bold>\n            The remission rate at 32\u00a0weeks was 50% for adults receiving ESK NS\u00a0+\u00a0OAD and 33% for adults receiving QTP XR\u00a0+\u00a0OAD. The cost-per-remitter for ESK NS\u00a0+\u00a0OAD compared with QTP XR\u00a0+\u00a0OAD was $3102.17 lower in the commercial setting and $456.12 lower in the Medicaid setting. Under the scenario analysis, the cost-per-remitter for ESK NS\u00a0+\u00a0OAD compared with QTP XR\u00a0+\u00a0OAD was $15,133.66 lower in the commercial setting and $12,487.62 lower in the Medicaid setting.\n            <jats:bold>Conclusion:<\/jats:bold>\n            The findings suggest that ESK NS\u00a0+\u00a0OAD is a cost-effective treatment for adults with TRD compared with QTP XR\u00a0+\u00a0OAD in the commercial and Medicaid settings.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0092","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:08:16Z","timestamp":1749460096000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression"],"prefix":"10.57264","author":[{"given":"Kristin","family":"Clemens","sequence":"first","affiliation":[{"name":"Right Solutions Mental Health, Gaithersburg, MD 20877, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Teeple","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Titusville, NJ 08560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Rive","sequence":"additional","affiliation":[{"name":"Janssen EMEA, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-6883","authenticated-orcid":false,"given":"Noam","family":"Kirson","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston, MA 02199, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-7201","authenticated-orcid":false,"given":"Urvi","family":"Desai","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston, MA 02199, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-9433","authenticated-orcid":false,"given":"Jason","family":"Doran","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston, MA 02199, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diab","family":"Eid","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston, MA 02199, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Qu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. Boston, MA 02199, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Bowrey","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Titusville, NJ 08560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Titusville, NJ 08560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"e_1_3_9_3_2","unstructured":"National Institute of Mental Health. Major Depression Definitions. (2023). Accessed: 28 November 2023: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression"},{"issue":"1","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12888-022-04165-x","article-title":"Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis","volume":"22","author":"Jain S","year":"2022","unstructured":"Jain S, Gupta S, Li VW, Suthoff E, Arnaud A. Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis. BMC Psychiatry 22(1), 542 (2022).","journal-title":"BMC Psychiatry"},{"issue":"6","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg PE","year":"2021","unstructured":"Greenberg PE, Fournier AA, Sisitsky T The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics 39(6), 653\u2013665 (2021).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_9_6_2","article-title":"Economic burden among patients with major depressive disorder: an analysis of healthcare resource use, work productivity, and direct and indirect costs by depression severity","author":"Chow W","year":"2019","unstructured":"Chow W, Doane MJ, Sheehan J, Alphs L, Le H. Economic burden among patients with major depressive disorder: an analysis of healthcare resource use, work productivity, and direct and indirect costs by depression severity. Am. J. Manag. Care (2019). (Supplements and Featured Publications. February 2019). Available at: https:\/\/www.ajmc.com\/view\/economic-burden-mdd","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"20m13699","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava M","year":"2021","unstructured":"Zhdanava M, Pilon D, Ghelerter I The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J. Clin. Psychiatry 82(2), 20m13699 (2021).","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"e_1_3_9_8_2","first-page":"823","article-title":"Economic burden of treatment-resistant depression on the U.S. Health care system","volume":"25","author":"Sussman M","year":"2019","unstructured":"Sussman M, O'Sullivan AK, Shah A, Olfson M, Menzin J. Economic burden of treatment-resistant depression on the U.S. Health care system. J. Manag. Care Spec. Pharm. 25(7), 823\u2013835 (2019).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"8","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013","volume":"65","author":"Mrazek DA","year":"2014","unstructured":"Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013. Psychiatr. Serv. 65(8), 977\u2013987 (2014).","journal-title":"Psychiatr. Serv."},{"key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos D","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr. Dis. Treat. 16, 221\u2013234 (2020).","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.31887\/DCNS.2014.16.1\/sdelaloye","article-title":"Deep brain stimulation in the treatment of depression","volume":"16","author":"Delaloye S","year":"2014","unstructured":"Delaloye S, Holtzheimer PE. Deep brain stimulation in the treatment of depression. Dialogues Clin. Neurosci. 16(1), 83\u201391 (2014).","journal-title":"Dialogues Clin. Neurosci."},{"issue":"3","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14737167.2023.2167712","article-title":"Adherence to augmentation therapy for the treatment of major depressive disorder","volume":"23","author":"Forma F","year":"2023","unstructured":"Forma F, Liberman JN, Rui P, Ruetsch C. Adherence to augmentation therapy for the treatment of major depressive disorder. Expert Rev. Pharmacoecon Outcomes Res. 23(3), 327\u2013335 (2023).","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"issue":"8","key":"e_1_3_9_13_2","first-page":"S235","article-title":"Atypical antipsychotics and the burden of disease","volume":"11","author":"Simpson GM","year":"2005","unstructured":"Simpson GM. Atypical antipsychotics and the burden of disease. Am. J. Manag. Care 11(Suppl. 8), S235\u2013S241 (2005).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_9_14_2","unstructured":"Johnson & Johnson. Spravato important safety information. (2023). Accessed: 28 November 2023: https:\/\/www.spravato.com\/?&utm_source=google&utm_medium=cpc&utm_campaign=GO-USA-ENG-PS-Spravato-BC-PH-RN-DTC_Core_HV&utm_content=Spravato+-+HV&utm_term=spravato&gclid=CjwKCAiAmZGrBhAnEiwAo9qHiUIgdFyx45wROgSCx0MrK5N0PWtHWH6LZnpUUqUNVagqkN1h9KfuqxoCcpAQAvD_BwE&gclsrc=aw.ds"},{"issue":"14","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif A","year":"2023","unstructured":"Reif A, Bitter I, Buyze J Esketamine nasal spray versus quetiapine for treatment-resistant depression. N. Engl. J. Med. 389(14), 1298\u20131309 (2023).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_16_2","unstructured":"National Library of Medicine. A long-term comparison of esketamine nasal spray versus quetiapine extended release both in combination with a selective serotonin reuptake inhibitor\/serotonin-norepinephrine reuptake inhibitor in participants with treatment resistant major depressive disorder (ESCAPE-TRD). (2023). Accessed: 28 November 2023: https:\/\/clinicaltrials.gov\/study\/NCT04338321"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0276"},{"key":"e_1_3_9_18_2","volume-title":"Costs associated with work productivity loss of patients with treatment-resistant depression treated with esketamine nasal spray versus quetiapine extended release: ESCAPE-TRD subgroup analysis [poster presentation]","author":"Teeple A","year":"2023","unstructured":"Teeple A, Zhdanava M, Shah A Costs associated with work productivity loss of patients with treatment-resistant depression treated with esketamine nasal spray versus quetiapine extended release: ESCAPE-TRD subgroup analysis [poster presentation]. Psych Congress, Nashville, TN, USA (6\u201310 September 2023)."},{"issue":"1","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1017\/S1092852924002451","article-title":"Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: A secondary analysis of the ESCAPE-TRD randomized clinical trial","volume":"30","author":"McIntyre RS","year":"2025","unstructured":"McIntyre RS, Mattingly G, Godinov Y Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: A secondary analysis of the ESCAPE-TRD randomized clinical trial. CNS Spectr. 30(1), e26 (2025).","journal-title":"CNS Spectr."},{"key":"e_1_3_9_20_2","unstructured":"Merative. Micromedex REDBOOK. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian. (Accessed: 28 November 2023)."},{"key":"e_1_3_9_21_2","unstructured":"United States Census Bureau. Current Population Survey (CPS). 2022. (2022). Accessed: 28 November 2023: https:\/\/www.census.gov\/programs-surveys\/cps.html."},{"key":"e_1_3_9_22_2","unstructured":"Bureau of Labor Statistics U.S. Department of Labor. American Time Use Survey \u2014 2021 results. (2022). Accessed: 28 November 2023"},{"key":"e_1_3_9_23_2","unstructured":"Centers for Medicare & Medicaid Services. Unit rebate amount calculation for non-innovator multiple source drugs. Accessed: 20 December 2023: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/unit-rebate-calculation\/unit-rebate-amount-calculation-for-non-innovator-multiple-source-drugs\/index.html"},{"key":"e_1_3_9_24_2","unstructured":"Johnson & Johnson Innovative Medicine Scientific Affairs. Data on File."},{"key":"e_1_3_9_25_2","unstructured":"Centers for Medicare & Medicaid Services. Unit rebate amount calculation for single source or innovator multiple source drugs. Accessed: 20 December 2023: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/unit-rebate-calculation\/unit-rebate-amount-calculation-for-single-source-or-innovator-multiple-source-drugs\/index.html"},{"issue":"7","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jamapsychiatry.2018.0768","article-title":"Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy\/psychotherapy for treatment-resistant depression in the United States","volume":"75","author":"Ross EL","year":"2018","unstructured":"Ross EL, Zivin K, Maixner DF. Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy\/psychotherapy for treatment-resistant depression in the United States. JAMA Psychiatry 75(7), 713\u2013722 (2018).","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"e0186950","DOI":"10.1371\/journal.pone.0186950","article-title":"Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients \u2013 a lifetime analysis","volume":"12","author":"Voigt J","year":"2017","unstructured":"Voigt J, Carpenter L, Leuchter A. Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients \u2013 a lifetime analysis. PLoS ONE 12(10), e0186950 (2017).","journal-title":"PLoS ONE"},{"issue":"2","key":"e_1_3_9_28_2","first-page":"17m11725","article-title":"Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database","volume":"79","author":"Amos TB","year":"2018","unstructured":"Amos TB, Tandon N, Lefebvre P Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J. Clin. Psychiatry 79(2), 17m11725 (2018).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0140"},{"key":"e_1_3_9_30_2","unstructured":"Guth M Drake P Rudowitz R Mohamed M. Understanding the intersection of Medicaid & work: a look at what the data say. (2023). Accessed: 28 November 2023: https:\/\/www.kff.org\/medicaid\/issue-brief\/understanding-the-intersection-of-medicaid-work-a-look-at-what-the-data-say\/"},{"key":"e_1_3_9_31_2","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-023-01732-5","article-title":"The correlation of esketamine with specific adverse events: a deep dive into the FAERSdatabase","author":"Jiang Y","year":"2023","unstructured":"Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H. The correlation of esketamine with specific adverse events: a deep dive into the FAERSdatabase.Eur. Arch. Psychiatry Clin. Neurosci. doi: 10.1007\/s00406-023-01732-5 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euroneuro.2024.05.009","article-title":"Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression","volume":"85","author":"McIntyre RS","year":"2024","unstructured":"McIntyre RS, Bitter I, Buyze J Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. Eur. Neuropsychopharmacol. 85, 58\u201365 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.083"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:08:23Z","timestamp":1749460103000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":31,"alternative-id":["10.57264\/cer-2024-0092"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0092","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"e240092"}}